Skip to main content
Clinical Trials/JPRN-UMIN000013088
JPRN-UMIN000013088Completed未知

Efficacy and safety of simeprevir with pegylated interferon alfa-2b and ribavirin in kidney transplant patients with chronic hepatitis C - Efficacy and safety of simeprevir with pegylated interferon alfa-2b and ribavirin in kidney transplant patients with chronic hepatitis C

Osaka University0 sites18 target enrollmentStarted: February 6, 2014Last updated:
Conditions

Trial Snapshot

Phase
未知
Status
Completed
Enrollment
18

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional,observational

Eligibility Criteria

Ages
20years-old to 70years-old (—)
Sex
All

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1) Co-infection with hepatitis B virus 2) Co-infection with anti-human immunodeficiency virus 3) Other forms of liver disease (alcohol liver disease, autoimmune hepatitis etc.) 4) Decompensated cirrhosis, Liver failure 5) Contraindication to pegylated interferon 6) Contraindication to ribavirin

Investigators

Similar Trials